Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2005
Human mesenchymal stem cells in rodent whole-embryo culture are reprogrammed to contribute to kidney tissuesTakashi Yokoo, Toya Ohashi, Jin Song Shen, et al.
Chemical & Pharmaceutical Bulletin|November 1, 2021
Discovery of DS68702229 as a Potent, Orally Available NAMPT (Nicotinamide Phosphoribosyltransferase) ActivatorMayuko Akiu, Takashi Tsuji, Kouki Iida, et al.
Molecular Genetics and Metabolism|November 6, 2010
Pathology of the first autopsy case diagnosed as mucolipidosis type III α/β suggesting autophagic dysfunctionHiroshi Kobayashi, Junko Takahashi-Fujigasaki, Takahiro Fukuda, et al.
Critical Care Medicine|April 1, 2024
Quantifying the Impact of Alternative Definitions of Sepsis-Associated Acute Kidney Injury on its Incidence and Outcomes: A Systematic Review and Meta-AnalysisLachlan H Donaldson, Ruan Vlok, Ken Sakurai, et al.
Molecular Genetics and Metabolism Reports|July 5, 2022
The role of native T1 values on the evaluation of cardiac manifestation in Japanese Fabry disease patientsIkuko Anan, Toru Sakuma, Eiko Fukuro, et al.
Frontiers in Cardiovascular Medicine|February 1, 2021
Characteristics of the Electrocardiogram in Japanese Fabry Patients Under Long-Term Enzyme Replacement TherapySatoshi Morimoto, Ayumi Nojiri, Eiko Fukuro, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 4, 2024
Role of Longitudinal Strain in the Evaluation of Contractile Dysfunction in Japanese Fabry Disease PatientsAyumi Nojiri, Satoshi Morimoto, Eiko Fukuro, et al.
Journal of Pharmacological and Toxicological Methods|May 1, 2020
Comprehensive analysis of cardiac function, blood biomarkers and histopathology for milrinone-induced cardiotoxicity in cynomolgus monkeysKatsuyoshi Chiba, Tomomichi Ishizaka, Yu Yoshimatsu, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2021
Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibitionMayuko Akiu, Takashi Tsuji, Yoshitaka Sogawa, et al.
Molecular Genetics and Metabolism|March 6, 2010
Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy caseHiroshi Kobayashi, Yohta Shimada, Masahiro Ikegami, et al.
Pageof 4